SALT LAKE CITY, Aug. 21, 2024 (GLOBE NEWSWIRE) — Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced Myriad management will participate in two upcoming investor healthcare conferences.
- The Wells Fargo Healthcare Conference in a fireside chat featuring Scott Leffler, Chief Financial Officer, on Sept. 4, 2024 at 1:30pm ET.
- The Morgan Stanley Healthcare Conference in a fireside chat featuring Paul J. Diaz, President and CEO, on Sept. 5, 2024 at 7:00am ET.
Links to the live and archived webcasts of both presentations can be viewed at investor.myriad.com.
About Myriad Genetics
Myriad Genetics is a leading genetic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. For more information, visit www.myriad.com.
Investor Contact
Matt Scalo
(801) 584-3532
IR@myriad.com
Media Contact
Glenn Farrell
(385) 318-3718
PR@myriad.com


Đề xuất
Educational Webinar: Unlocking the Potential of PSMA Therapy, A Next‑Generation Portfolio Approach
Weihai Global Partner Business Center Undertakes Investment Promotion Activities in Xi’an
Feldspar unveils world’s first surface-based force measurement platform, announces engineering partnership and opens capital raise
A Paradise Acquisition Corp. Announces Intention to Voluntarily Delist from The Nasdaq Stock Market LLC, Conditional Upon Consummation of its Pending Business Combination with Enhanced Ltd
Sondo AI Marks One-Year Milestone as One of the Hottest AI Music Video Generators Transforming Music Video Creation
Iovance Biotherapeutics to Report First Quarter 2026 Financial Results and Corporate Updates on Thursday, May 7, 2026